CEL-SCI to Present at the 2015 BIO International Convention
June 16 2015 - 8:30AM
Business Wire
CEL-SCI Corporation (NYSE MKT: CVM) (“CEL SCI” or the
“Company”), a late-stage cancer immunotherapy company, today
announced that it will present at the 2015 BIO International
Convention on Wednesday, June 17, 2015. Hosted by the Biotechnology
Industry Organization (BIO), this year’s global event for
biotechnology will take place June 15-18, 2015 at the Pennsylvania
Convention Center in Philadelphia, PA.
The Company presentation by Geert Kersten, Chief Executive
Officer, is scheduled to begin at 4:15 p.m. ET in Theater 4 of the
Pennsylvania Convention Center. A live webcast of the presentation
may be accessed via the Investor Relations section of CEL-SCI’s
corporate website at under the heading CEL-SCI Presentations. The
webcast replay will be available approximately one hour after the
presentation ends and will be archived for 90 days.
About the BIO International Convention
The BIO International Convention is considered one of the
world's largest, most influential biotech meetings and regularly
attracts 15,000 of the most powerful biotech and pharma players
from 65 countries, offering powerful business partnering,
networking and education that go far beyond professional
development.
About CEL-SCI Corporation
CEL-SCI’s work is focused on finding the best way to activate
the immune system to fight cancer and infectious diseases. Its lead
investigational therapy, Multikine (Leukocyte Interleukin,
Injection), is currently being studied in a pivotal Phase 3
clinical trial as a potential neoadjuvant treatment for patients
with squamous cell carcinoma of the head and neck. If the study
endpoint, which is a 10% improvement in overall survival of the
subjects treated with the Multikine treatment regimen plus the
current SOC as compared to subjects treated with the current SOC
only, is satisfied, the study results will be used to support
applications that the Company plans to submit to regulatory
agencies in order to seek commercial marketing approvals for
Multikine in major markets around the world. Additional clinical
indications for Multikine that are being investigated include the
treatment of cervical dysplasia in HIV/HPV co-infected women, and
the treatment of peri-anal warts in HIV/HPV co-infected men and
women. A Phase 1 trial of the former indication has been completed
at the University of Maryland. The latter indication is now in a
Phase 1 trial in conjunction with the U.S. Naval Medical Center,
San Diego, under a Cooperative Research and Development Agreement,
or CRADA.
CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand
Epitope Antigen Presentation System) technology for the potential
treatment of pandemic influenza in hospitalized patients and as a
potential vaccine for the treatment of rheumatoid arthritis.
The Company has operations in Vienna, Virginia, and in/near
Baltimore, Maryland. For more information, please visit
www.cel-sci.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. When used in this press release, the words “intends,”
“believes,” “anticipated,” “plans” and “expects,” and similar
expressions, are intended to identify forward-looking statements.
Such statements are subject to risks and uncertainties that could
cause actual results to differ materially from those projected.
Factors that could cause or contribute to such differences include,
an inability to duplicate the clinical results demonstrated in
clinical studies, timely development of any potential products that
can be shown to be safe and effective, receiving necessary
regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary
capital and the risk factors set forth from time to time in CEL-SCI
Corporation’s filings with the Securities and Exchange Commission,
including but not limited to its report on Form 10-K and 10-K/A for
the year ended September 30, 2014. The Company undertakes no
obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150616005627/en/
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2023 to Apr 2024